Medical Complexity Seen in 12 Percent of Military-Connected Children
By Elana Gotkine HealthDay Reporter
FRIDAY, April 11, 2025 -- The cumulative incidence of children with medical complexity (CMC)-defining diagnoses in military-connected children is 12.0 percent by age 60 months, according to a study published online April 8 in Pediatrics.
JoAnna K. Leyenaar, M.D., Ph.D., M.P.H., from Dartmouth Health Children's in Lebanon, New Hampshire, and colleagues identified CMC born between 2005 and 2015 and diagnosed from birth until age 60 months. The cumulative incidence of medical complexity was estimated and associations between birth outcomes and CMC-defining diagnoses were calculated.
The researchers found that the estimated cumulative incidence of CMC-defining diagnoses by age 60 months was 12.0 percent among 975,233 live births, with one-third and two-thirds diagnosed during the neonatal period and during infancy, respectively. The highest risks were seen for children born with versus without congenital anomalies, those born very preterm versus nonpreterm, and those with very low birthweight versus normal/high birthweight (adjusted hazard ratios, 25.2, 17.6, and 13.7, respectively).
"Although preterm birth, low birthweight, and congenital anomalies were strong risk factors for medical complexity, most CMC identified in this study did not experience these birth outcomes," the authors write. "These results provide valuable data to justify early intervention services as well as other programs and policies that support health care access, regularly scheduled health assessments, and care coordination for military-connected children."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-04-12 06:00
Read more

- Globally, One in 13 Youth Experience Nocturnal Enuresis
- New Data on Investigational Therapy Doxecitine and Doxribtimine for Thymidine Kinase 2 Deficiency Presented at Muscular Dystrophy Association (MDA) 2025 Conference
- Long-Term Gantenerumab May Slow Decline in Dominantly Inherited Alzheimer Disease
- Merck’s Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) Keytruda® (pembrolizumab) in Pivotal 3475A-D77 Trial
- Blue Laser Vaporization Effective for Benign Prostatic Hyperplasia
- Sensorized T-Shirt Enables Early Discharge After Oncological Urology Surgery
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions